Moderna Inc (MRNA)
Quick ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 2,907,000 | 3,205,000 | 6,848,000 | 2,624,000 | 236,000 |
| Short-term investments | US$ in thousands | 5,697,000 | 6,697,000 | 3,879,000 | 1,983,760 | 867,124 |
| Receivables | US$ in thousands | 1,020,000 | 1,622,000 | 3,245,000 | 1,400,280 | 12,204 |
| Total current liabilities | US$ in thousands | 3,015,000 | 4,923,000 | 9,128,000 | 4,389,000 | 143,115 |
| Quick ratio | 3.19 | 2.34 | 1.53 | 1.37 | 7.79 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($2,907,000K
+ $5,697,000K
+ $1,020,000K)
÷ $3,015,000K
= 3.19
The quick ratio of Moderna Inc has exhibited variability over the past five years, ranging from 1.42 in 2020 to 7.88 in 2019. The quick ratio measures the company's ability to meet its short-term obligations using its most liquid assets. A higher quick ratio indicates a stronger ability to cover current liabilities with liquid assets.
In 2023, Moderna's quick ratio improved significantly to 3.33 from 2.49 in 2022, signaling an enhanced liquidity position. This increase suggests that Moderna may have increased its liquid assets or reduced its current liabilities compared to the previous year, improving its ability to meet short-term obligations.
It is worth noting that the quick ratio of Moderna in 2019 was considerably high at 7.88, indicating a robust liquidity position at that time. However, the quick ratio dropped in the following years before showing a notable improvement in 2023.
Overall, the increasing trend in Moderna's quick ratio from 2020 to 2023 suggests a strengthening liquidity position, which may enhance the company's ability to manage short-term financial obligations effectively.
Peer comparison
Dec 31, 2023